RAFFLES MEDICAL GROUP LTD Strong sustainable growth outlook

4 March 2015

SINGAPORE | HEALTHCARE | UPDATE   

Strong growth prospects supported by government initiatives and ageing demographics. Expanding Raffles Hospital’s space by 70% to cater for future growth. Reiterate Accumulate on strong growth prospects with unchanged TP of S$4.49.

Investment Merits   

Key beneficiary of government initiative’s to shift patients from overburdened public healthcare system to private this year. Further growth from new five-story commercial mall and hospital extension, expected to be ready in 1Q16 and 1Q17 respectively. Sustainable growth driven by ageing population and longer life expectancy.

ACCUMULATE (MAINTAIN) SGD 3.93 SGD 0.06 SGD 4.49 15.8%

CLOSING PRICE FORECAST DIV TARGET PRICE TOTAL RETURN COMPANY DATA O/S SHA RES (M N) :

565

M A RKET CA P (USD mn / SGD mn) :

1619.5 / 2207.9

52 - WK HI/LO (SGD) :

4.11/ 3.11

3M A verage Daily T/O (mn) :

0.33

MAJOR SHAREHOLDERS (%)

Raffles Medical Group expects to see greater increase in patients visiting its medical clinics as elderly (aged 65 and above) Singaporeans would be eligible for government medical and dental care subsidies from Sep-2014. It may also benefit under a emergency care collaboration with the Singapore Civil Defence Force (SCDF) whereby its hospital would start receiving non-critical ambulance cases from mid-2015.

RAFFLES MEDICAL HOLDINGS CHOON YONG LOO ABERDEEN FIL LIMITED S&D HOLDINGS PTE LTD

Construction works on both hospital extension and the new commercial mall projects is in progress. Raffles Hospital would add an additional 200,000 sqf or 73% to its existing 300,000 sqf of gross floor area (GFA) upon completion of the hospital extension works.

PRICE PERFORMANCE (%) 1M T H

3 M TH

1Y R

COM P A NY

(1.8)

1.8

22.9

The new S$120 million mall would be situated in Holland Village, a popular shopping and dining location among locals and expatriates. The mall would accommodate the group’s own outpatient medical and specialist clinics for its patients. About 36,000 sqf of space would be leased out to other tenants, generating additional rental revenue which we estimated at about S$6 million (based on S$13.73 psf/mth median for retail outlets in Holland Avenue and Holland Road from URA REALIS data over Jan-Dec 14 period).

STI RETURN

(0.5)

2.8

12.8

38.5% 10.0% 6.0% 4.3% 3.2%

PRICE VS. STI 4.20

3.70

3.20

Plans for growth expansion overseas  

Intend to build a 200-bed private hospital in Shenzhen to provide medical and healthcare services in the Pearl River Delta region in Feb 2013. Signed framework agreement in Sep 2013 to build a 300-bed private hospital in Pudong, Shanghai.

2.70 Mar-14

Jun-14 Sep-14 RFMD SP Equity

Dec-14 Mar-15 FSSTI Index

So urce: B lo o mberg, P SR

KEY FINANCIALS

Key risks

SGD M N

F Y 13

F Y 14

F Y 15e

F Y 16 e

   

Revenue

341

375

413

460

EB ITDA

78

87

95

111

NP A T (adj.)

61

65

71

82

Patients flow from private to public healthcare system on better capacity and quality. Rising medical staff costs. Execution risks or delays in the two development projects. Tighter competition from regional peers.

EP S (adj.)

0.11

0.12

0.13

0.14

P ER, x (adj.)

28.1

33.7

31.1

27.4

P /B V, x

Investment Actions Maintain Accumulate on strong sustainable growth outlook ahead with unchanged TP of S$4.49.

DP S (S cts) Div Yield, % ROE, %

3.6

4.1

3.7

3.4

5.00

5.50

6.00

6.50

1.6%

1.4%

1.5%

1.7%

14.1%

12.8%

12.9%

13.4%

So urce: Co mpany Data, P SR est.

VALUATION METHOD DCF (WACC: 7.5%; terminal g: 3.0%) Colin Tan

(+65 6531 1221)

[email protected]

Page | 1 | PHILLIP SECURITIES RESEARCH (SINGAPORE) MCI (P) 019/11/2014 Ref. No.: SG2015_0088

RAFFLES MEDICAL GROUP LTD RESULTS Fig 1: Singapore old-age support ratio (x) residents aged 65y & above ('000)

('000) 500

old-age support ratio (x)

400 300

8.1

7.8

7.7

7.6

7.5

7.4

7.2

6.7

6.4

6.0

2012

2013

2014

200 100 0 2005

2006

2007

2008

2009

2010

2011

Source: SingStat, Phillip Securities Research (Singapore)

Fig 2: Revenue growth (m n)

Revenue (S$mn)

500

YoY Growth (%)

14.2

14.1

400

9.4

9.9

10.3

FY13

FY14

FY15e

9.4

11.2

300 200 100 0 FY10

FY11

FY12

FY16e

Source: Company, Phillip Securities Research (Singapore) estimates

Fig 3: Profit margins (m n)

90

PATMI, adj (S$mn) 23.8

EBITDA margin (%)

Net margin (%) 24.1

23.7

22.6

23.0

23.2

23.0

17.3

17.2

FY14

FY15e

60

30

17.7

17.7

FY10

FY11

17.8 17.0

17.9

0 FY12

FY13

FY16e

Source: Company, Phillip Securities Research (Singapore) estimates

Fig 4: Dividends payout (S cts)

DPS (S cts)

EPS (S cts)

Payout (%)

20 15

40

42

45

43

46

44

32 10 5

6.5

5.0

6.0

4.0

4.5

5.5

3.5 FY10

FY11

FY12

FY13

FY14

FY15e

FY16e

0

Source: Company, Phillip Securities Research (Singapore) estimates

Page | 2 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

RAFFLES MEDICAL GROUP LTD RESULTS Fig 5: Selected peer comparison Mkt Cap Ent Val P/E P/B EV/EBITDA Div Yield ROE FYE (S$m) (S$m) FY14/15e FY15/16e FY14/15e FY15/16e FY14/15e FY15/16e FY14/15e FY15/16e FY14/15e FY15/16e Dec 2,208 2,066 29.2 25.7 3.8 3.4 21.0 17.8 1.4 1.5 13.6 14.2 Peers' average: 30.0 25.8 5.3 4.6 16.9 14.8 2.0 2.1 20.2 20.1 IHH SP IHH HEALTHCARE B Dec 16,848 18,234 47.2 38.3 2.2 2.2 21.8 18.6 0.5 0.6 4.8 5.7 RHC AU RAMSAY HEALTH Jun 14,646 17,897 34.2 29.2 7.8 6.9 15.5 13.3 1.5 1.8 22.3 23.7 RHC AU RAMSAY HEALTH Jun 14,646 17,897 34.2 29.2 7.8 6.9 15.5 13.3 1.5 1.8 22.3 23.7 RYM NZ RYMAN HEALTHCARE Mar 4,136 4,519 25.6 22.2 3.9 3.4 23.1 20.0 1.7 1.9 13.6 14.9 PRY AU PRIMARY HEALTH Jun 2,654 3,879 18.6 16.9 1.0 1.0 8.7 8.3 4.0 4.2 5.6 5.7 KPJ MK KPJ HEALTHCARE Dec 1,567 1,964 30.1 27.6 3.1 2.9 15.0 13.4 1.7 1.8 10.8 10.9 TKMED SP TALKMED GROUP LT Dec 693 652 17.0 16.2 11.7 9.6 13.4 12.8 4.4 4.5 74.0 65.0 QNM SP Q&M DENTAL GROUP Dec 417 430 31.5 26.8 4.5 4.1 19.8 16.6 1.5 1.7 15.2 17.1 ISEC SP ISEC HEALTHCARE Dec 215 206 31.3 26.1 #N/A N/A #N/A N/A 19.3 16.6 0.9 0.9 13.4 14.3 BB Ticker Company RFMD SP RAFFLES MEDICAL

Source: Bloomberg

Page | 3 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

RAFFLES MEDICAL GROUP LTD RESULTS

Financials Income Statement

Balance Sheet

Y/E Dec, SGD mn

FY12

FY13

FY14

FY15e

FY16e

Revenue Opera ti ng expens es EBITDA Depreci a ti on & Amorti s a ti on EBIT As s oci a tes & JVs Net Fi na nce (Expens e)/Inc Other i tems PBT Ta x PAT Mi nori ty i nteres t Net Income, reported Net Income, adj.

312 (241) 70 (8) 62 0 0 4 67 (9) 57 (0) 57 53

341 (263) 78 (8) 70 0 1 24 95 (10) 85 (0) 85 61

375 (288) 87 (10) 77 0 1 3 81 (13) 68 (0) 68 65

413 (318) 95 (10) 85 0 1 3 89 (15) 74 (0) 74 71

460 (349) 111 (12) 98 0 1 3 102 (17) 86 (0) 85 82

Per share data

Y/E Dec, SG cents EPS, reported EPS, a dj. DPS BVPS

FY12

FY13

FY14

FY15e

FY16e

ASSETS PPE Inta ngi bl es Inves tment properti es Others Total non-current assets Tra de & other recei va bl es Ca s h ba l a nce Others Total current assets Total Assets

154 0 195 0 349 38 102 5 146 495

154 0 100 0 254 44 266 9 319 573

228 0 228 3 459 37 150 9 196 655

363 0 228 3 594 54 87 13 153 747

464 0 228 3 695 60 40 14 113 808

LIABILITIES Short-term debt Tra de a nd other pa ya bl es Others Total current liabilities Long-term debt Others

20 66 17 104 0 2

5 73 20 98 0 2

6 74 24 105 0 10

6 97 24 127 0 10

6 106 24 137 0 10

2

2

10

10

10

1 388

1 473

1 539

2 609

2 659

FY12

FY13

FY14

FY15e

FY16e

FY12

FY13

FY14

FY15e

FY16e

Total non-current liabilities

10.53 9.80 4.50 71.29

15.43 11.02 5.00 85.31

12.09 11.55 5.50 95.50

13.03 12.50 6.00 106.12

14.72 14.21 6.50 112.86

EQUITY Mi nori ty i nteres t Shareholder Equity

FY12

FY13

FY14

FY15e

FY16e

Cash Flows

Y/E Dec, SGD mn

Y/E Dec, SGD mn

Valuation Ratios

Y/E Dec, SGD mn

CFO P/E (X), a dj. 26.7 28.1 33.7 31.1 27.4 PBT 67 95 81 89 102 P/B (X) 3.7 3.6 4.1 3.7 3.4 Adjus tments 6 (14) 9 9 12 EV/EBITDA (X) 19.1 18.6 23.6 22.2 19.5 WC cha nges 6 0 13 2 2 Di vi dend Yi el d (%) 1.7% 1.6% 1.4% 1.5% 1.7% Ca s h genera ted from ops 79 82 103 100 116 Growth & Margins (%) Ta xes pa i d, others (9) (10) (10) (15) (17) Growth Cashflow from ops 70 71 93 85 99 Revenue 14.2% 9.4% 9.9% 10.3% 11.2% CFI EBITDA 8.9% 11.4% 11.1% 9.4% 16.5% CAPEX, net (10) (8) (18) (145) (113) EBIT 8.9% 12.2% 10.4% 10.0% 15.6% Acqui s i ti on, others (1) 119 (188) 1 1 Net Income, a dj. 9.7% 14.5% 6.7% 10.0% 15.6% Cashflow from investing (10) 111 (206) (144) (112) Margins CFF EBITDA ma rgi n 22.6% 23.0% 23.2% 23.0% 24.1% Sha re i s s ua nce 4 6 8 9 0 EBIT ma rgi n 20.0% 20.5% 20.6% 20.6% 21.4% Loa ns , net of repa yments (1) (15) 1 0 0 Net Profi t Ma rgi n 17.0% 17.8% 17.3% 17.2% 17.9% Di vi dends (9) (10) (12) (13) (34) Key Ratios Others (0) (0) (0) 0 0 ROE (%) 14.6% 14.1% 12.8% 12.9% 13.4% Cashflow from financing (6) (19) (3) (4) (34) ROA (%) 11.5% 11.3% 10.5% 10.6% 11.0% Effects of excha nge ra tes (0) 0 0 0 0 Net change in cash 53 163 (116) (63) (47) Interes t covera ge (X) 7.9 8.5 8.0 8.4 7.9 CCE, end 102 266 150 87 40 Net gea ri ng (X) Net ca s hNet ca s hNet ca s hNet ca s hNet ca s h Source: Compa ny, Phi l l i p Securi ti es Res ea rch (Si nga pore) Es ti ma tes *Forward multiples and yields are based on current market price; historical multiples and yields are based on historical market price.

Page | 4 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

RAFFLES MEDICAL GROUP LTD RESULTS Ratings History Market Price Target Price

4.90

Source: Bl oomberg, PSR

4.40 3.90 3.40 2.90

2.40

Oct-15

Jul-15

Apr-15

Jan-15

Oct-14

Jul-14

Apr-14

Jan-14

Oct-13

Jul-13

Apr-13

Jan-13

1 2 3 4 5 PSR Rating System Total Returns Recommendation Rating > +20% Buy 1 +5% to +20% Accumul a te 2 -5% to +5% Neutra l 3 -5% to -20% Reduce 4 <-20% Sel l 5 Remarks We do not ba s e our recommenda tions entirel y on the a bove qua ntitative return ba nds . We cons i der qua l i tative fa ctors l i ke (but not l i mi ted to) a s tock's ri s k rewa rd profi l e, ma rket s entiment, recent ra te of s ha re pri ce a ppreci a tion, pres ence or a bs ence of s tock pri ce ca tal ys ts , a nd s pecul a tive undertones s urroundi ng the s tock, before ma ki ng our fi na l recommenda tion

Page | 5 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

RAFFLES MEDICAL GROUP LTD RESULTS Contact Information (Singapore Research Team) Management Chan Wai Chee (CEO, Research - Special Opportunities)

Macro | Equities Soh Lin Sin Bakhteyar Osama

[email protected]

Research Operations Officer Jaelyn Chin [email protected]

Market Analyst | Equities Kenneth Koh [email protected]

US Equities Wong Yong Kai

[email protected]

Real Estate Caroline Tay

REITs Dehong Tan

[email protected]

[email protected]

Finance | Offshore Marine Benjamin Ong [email protected] Telecoms | Technology Colin Tan

[email protected]

[email protected] SINGAPORE Phillip Securities Pte Ltd Raffles City Tower 250, North Bridge Road #06-00 Singapore 179101 Tel +65 6533 6001 Fax +65 6535 6631 Website: www.poems.com.sg

[email protected]

Transport & Logistics Richard Leow, [email protected] CFTe Contact Information (Regional Member Companies) MALAYSIA Phillip Capital Management Sdn Bhd B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel +603 2162 8841 Fax +603 2166 5099 Website: www.poems.com.my

HONG KONG Phillip Securities (HK) Ltd 11/F United Centre 95 Queensway Hong Kong Tel +852 2277 6600 Fax +852 2868 5307 Websites: www.phillip.com.hk

JAPAN Phillip Securities Japan, Ltd. 4-2 Nihonbashi Kabuto-cho Chuo-ku, Tokyo 103-0026 Tel +81-3 3666 2101 Fax +81-3 3666 6090 Website: www.phillip.co.jp

INDONESIA PT Phillip Securities Indonesia ANZ Tower Level 23B, Jl Jend Sudirman Kav 33A Jakarta 10220 – Indonesia Tel +62-21 5790 0800 Fax +62-21 5790 0809 Website: www.phillip.co.id

CHINA Phillip Financial Advisory (Shanghai) Co Ltd No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200 Fax +86-21 6351 2940 Website: www.phillip.com.cn

THAILAND Phillip Securities (Thailand) Public Co. Ltd 15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921 Website www.phillip.co.th

FRANCE King & Shaxson Capital Limited 3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel +33-1 45633100 Fax +33-1 45636017 Website: www.kingandshaxson.com

UNITED KINGDOM King & Shaxson Capital Limited 6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950 Fax +44-20 7626 1757 Website: www.kingandshaxson.com

UNITED STATES Phillip Futures Inc 141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1-312 356 9000 Fax +1-312 356 9005 Website: www.phillipusa.com

AUSTRALIA Phillip Capital Limited Level 12, 15 William Street, Melbourne, Victoria 3000, Australia Tel +61-03 9629 8288 Fax +61-03 9629 8882 Website: www.phillipcapital.com.au

SRI LANKA Asha Phillip Securities Limited No-10 Prince Alfred Tower, Alfred House Gardens, Colombo 03, Sri Lanka Tel: (94) 11 2429 100 Fax: (94) 11 2429 199 Website: www.ashaphillip.net

TURKEY PhillipCapital Menkul Degerler Dr. Cemil Bengü Cad. Hak Is Merkezi No. 2 Kat. 6A Caglayan 34403 Istanbul, Turkey Tel: 0212 296 84 84 Fax: 0212 233 69 29 Website: www.phillipcapital.com.tr

DUBAI Phillip Futures DMCC Member of the Dubai Gold and Commodities Exchange (DGCX) Unit No 601, Plot No 58, White Crown Bldg, Sheikh Zayed Road, P.O.Box 212291 Dubai-UAE Tel: +971-4-3325052 / Fax: + 971-4-3328895 Website: www.phillipcapital.in

INDIA PhillipCapital (India) Private Limited No.1, 18th Floor Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel West, Mumbai 400-013 Maharashtra, India Tel: +91-22-2300 2999 / Fax: +91-22-2300 2969 Website: www.phillipcapital.in

Page | 6 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

RAFFLES MEDICAL GROUP LTD RESULTS

Important Information This publication is prepared by Phillip Securities Research Pte Ltd., 250 North Bridge Road, #06-00, Raffles City Tower, Singapore 179101 (Registration Number: 198803136N), which is regulated by the Monetary Authority of Singapore (“Phillip Securities Research”). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below. This publication has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this document by mistake, please delete or destroy it, and notify the sender immediately. Phillip Securities Research shall not be liable for any direct or consequential loss arising from any use of material contained in this publication. The information contained in this publication has been obtained from public sources, which Phillip Securities Research has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this publication are based on such information and are expressions of belief of the individual author or the indicated source (as applicable) only. Phillip Securities Research has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete, appropriate or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the preparation or issuance of this report, (i) be liable in any manner whatsoever for any consequences (including but not limited to any special, direct, indirect, incidental or consequential losses, loss of profits and damages) of any reliance or usage of this publication or (ii) accept any legal responsibility from any person who receives this publication, even if it has been advised of the possibility of such damages. You must make the final investment decision and accept all responsibility for your investment decision, including, but not limited to your reliance on the information, data and/or other materials presented in this publication. Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this publication is not indicative of future results. This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This publication should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks. Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this research should take into account existing public information, including any registered prospectus in respect of such product. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this publication, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this publication. Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment. To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold a interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this publication. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, which is not reflected in this material, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the preparation or issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the preparation or issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this material. The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction. Section 27 of the Financial Advisers Act (Cap. 110) of Singapore and the MAS Notice on Recommendations on Investment Products (FAA-N01) do not apply in respect of this publication. This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products. Please contact Phillip Securities Research at [65 65311240] in respect of any matters arising from, or in connection with, this document. This report is only for the purpose of distribution in Singapore.

Page | 7 | PHILLIP SECURITIES RESEARCH (SINGAPORE)